Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Tissue Regenix bolsters board with Consort chief

Jonathan Glenn has run inhaler specialist Consort since 2007 and previously held senior financial roles across the medical industry
Tissue Regenix bolsters board with Consort chief
Tissue Regenix has patented a cell-washing technology

Regenerative med-tech Tissue Regenix (LON:TRX) has appointed the chief executive of Consort Medical to its board as a non-executive.

Jonathan Glenn has run inhaler specialist Consort since 2007 and previously held senior financial roles across the medical industry including seven years at Celltech where he played a key role in the acquisitions of Chiroscience, Medeva and OGS.

John Samuel, Tissue Regenix’s chairman, he was very pleased Glenn was joining the business.

“He has excellent experience in the medical devices market.”

Tissue Regenix has patented a cell-washing technology that it is using to pioneer replacement body parts including skin, knee cartilages, ligaments and heart valves.

PhilW.jpg
Why Invest In Tissue Regenix Group PLC? Read More Here

Register here to be notified of future TRX Company articles
View full TRX profile

Tissue Regenix Group PLC Timeline

Related Articles

cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
Blood testing
February 13 2017
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.
AZN2.jpg
January 10 2017
We look at what looks to be a savvy investment by the UK biotech.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.